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Background: ﬁrst CF patient in Czech republic was diagnosed in 1946. Improving
care led to improved survival and ﬁrst adult CF centre was established in 1987.
Today, ﬁve adult CF centres exist in Czech republic.
Methods: searching in databases and patient ﬁles for adult CF patients, CFTR
mutations, pulmonary and extrapulmonary complications, and selected modalities
of treatment.
Results: totally 184 adult CF patients (100M, 84F) were identiﬁed in databases.
Fifty-four patients died or were lost from evidence. Current group of CF adults
consists of 130 patients (68M, 62F) aged 27.5±6.3 years. 50.8% of them are
colonized with P. aeruginosa and 35.4% with B. cepacia. 31.5% of patients have
normal FEV1, 24.6% mild (FEV1 60−79% pred.), 23.1% moderate (FEV1 45−59%
pred.) and 20.8% severe (FEV1< 45% pred.) obstruction. 81.5% of patients have
exocrine pancreatic insufﬁciency and 18.5% is malnourished (BMI< 18.5 kg/m2).
23.8% of patients have liver disease, 29.2% diabetes mellitus or impaired glucose
tolerance and 41.4% bone disease. 72.3% of patients recieve rhDNase, 29.2%
tobramycin or colistin inhalations, 14.6% azithromycin, 40.0% nutritional support
and 6.2% LTOT. Six patients underwent lung transplantation and four are on waiting
list.
Conclusion: complex care based on european standards and given in specialized
centres is the only possibility for further improvement of survival and quality of
life of CF patients.
Supported by: MZO 000 64203 6405.
350 Cystic ﬁbrosis (CF) and the risk of pancreatic cancer (PDAC)
A. Lowenfels1, P. Maisonneuve2, B. Marshall3. 1Surgery, New York Medical
College, Valhalla, NY, USA; 2Epidemiology Unit, European Institute of Oncology,
Milan, Italy; 3Cystic Fibrosis Foundation, Bethesda, MD, USA
Introduction and Aim: Previous reports have detected an excess risk of pancreas
cancer in patients with pancreatitis. In CF, pathologic changes have been noted in
all the digestive organs including the pancreas; at birth the pancreas of CF patients
already demonstrates marked histological abnormalities. The aim of this study was
to determine the overall risk of PDAC in patients with CF.
Method: We obtained information about patients with both CF and PDAC from
the USA and Canadian Cystic Fibrosis Patient Registries, from previous literature
reports, and by querying CF physicians and pathologists in the USA, Canada, and
Europe. The expected number of patients with PDAC for non-CF persons was
estimated from population-based data adjusted for age and sex. The risk of PDAC
in patients with CF was determined by comparing the observed with the expected
number of cases (standard incidence ratio-SIR).
Results: Over a 20 year period (1985–2004) we obtained reports of 9 patients
(5 male, 4 female) with both CF and PDAC. Median age at diagnosis of PDAC
was 35 years (range 18−58 years). Four patients were homozygous for the Delta
F508 mutation, one patient was heterozygous. 5 of the 9 patients had mild or
moderate lung disease. The expected number of PDAC patients in the non-CF
population adjusted for age and sex was 1.6, yielding an SIR or risk ratio of 5.6
(95% CI = 4.1−17.1).
Conclusion: Based on data from North America and Europe, patients with CF
have an increased risk of PDAC which closely resembles the increased risk for
other digestive tract tumors. However compared to other causes of mortality in
CF patients, the absolute risk of PDAC in this population is negligible.
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Advances in management have lead to increased survival in CF. It is important
to establish whether this trend is associated with increased levels of employment.
The aim of this study was to examine employment status at a UK adult CF clinic
between 1996 and 2006.
Annual data is collected prospectively on all people with CF attending Papworth
Hospital. The clinic population in 1996 was 79 and in 2006 182. All subjects were
>16 years of age. The Mean FEV1% pred (±sd) in 1996 was 51.6% (±27.3) and
63.9% (±26.4)in 2006. Mean BMI (±sd) kg/m2 in 1996 was 20.9 (±3.67) kg/m2
and 21.5 (±2.86) kg/m2 in 2006.
In 1996, 30 (38%) patients were in employment, 26 (33%) in fulltime employment
and 4 (5%) in part-time employment. 40 (50%) were in full-time education, 6 (8%)
were unemployed, and 3 (4%) were full-time homemakers.
In 2006, 96 (53%) patients were in employment, 68 (38%) in fulltime employment
and 28 (15%) part-time employment. 32 (18%) were in full-time education,
46 (25%)were unemployed, and 8 (4%) were fulltime homemakers.
We compared national data for 2004 from the UK CF Registry. 2827 subjects
>16 years of age had employment data. 1350 (48%) were in employment,
1002 (36%) fulltime employment, 348 (12%) part-time employment. 514 (18%)were
in fulltime education, 789 (28%) unemployed, and 174 (6%) fulltime homemakers.
In conclusion we have conﬁrmed that signiﬁcantly more patients are in employment
in 2006 compared to 1996, largely through an increase in part-time employment.
Adolescents and adults with cystic ﬁbrosis should receive career advice to prepare
them for future employment.
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Introduction: Cystic ﬁbrosis is frequently associated to nasal polyposis.
Aims: To study the incidence of nasal polyposis in children and adolescents
with cystic ﬁbrosis, its possible association to age, gender, clinical manifestations,
genotype and chlorid level, and its evolution with topical corticosteroid therapy.
Methods: Clinical symptoms (pulmonary, pancreatic insufﬁciency, undernutrition,
nasal obstruction), sweat chlorid level, genotype and nasal endoscopic ﬁndings
were studied in 23 cystic ﬁbrosis patients. Polyposis was treated with topical
corticosteroid during 6 months, followed by a second nasal endoscopy.
Results: Nasal polyposis was found in 39.1% of the patients (ﬁve bilateral, four
unilateral), recurrent pneumonia in 82.6%, pancreatic insufﬁciency in 87% and
malnutrition in 74%. No association was seen between nasal polyposis and sweat
chlorid level, genotype, clinical sings of severity and nasal symptoms. Nasal polyps
were found in children older than six years. Seven patients improved polyposis with
corticosteroid therapy, six showed complete involution.
Conclusion: The study showed a high incidence of nasal polyposis in older children,
even in the absence of clinical nasal symptoms. Patients with CF and nasal polyposis
span the entire range of clinical severity. Topical corticosteroid therapy showed good
results. An interaction among pediatricians and otolaryngologist is necessary.
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